Venn Life Sciences Share News (VENN)

DIRECTOR DEALINGS: Venn Life Sciences Chairman Buys Shares

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Tuesday said Chairman David Evans bought 210,000 shares at a price of 20.5 pence per share. Following this transaction, Evans now holds 289,033 shares. Shares in the clinical trial services company were trading flat at 20.5 penc

Venn Life Sciences scores multi-million euro contract

AIM-listed clinical research organisation Venn Life Sciences announced it has scored a multi-million euro contract with a major European biotechnology company. The agreement, which is spread out over a year and a half and spans over seven European countries as well as a number of US sites, will see

Venn Life Sciences 2013 Loss Widens On Lower Revenue

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday posted a widened pretax loss in 2013, as it saw revenue decline, and announced a new contract win. The clinical research organisation posted a pretax loss of EUR1.8 million, widened from EUR1.2 million in the previous year, as

Venn Life Sciences Finance Director Resigns

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said its Finance Director Paul Foulger has given notice of intention to resign from its board from April 14. The pharmaceutical and biotechnology company said Foulger now plans to pursue a full-time role within another public c

UK MORNING BRIEFING: Shares Open Lower; BP Gets US Bid Approval

LONDON (Alliance News) - Shares have opened lower Friday on geopolitical worries ahead of the weekend, despite some good news for UK companies.

The US government on Thursday decided to lift the ban on BP from federal government contracts imposed after the Deepwater

Venn Life Sciences Raises GBP1 Million In Placing

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said it has raised GBP1 million before expenses by placing 5.3 million shares at 19 pence each, funds it will use to develop the Labskin and potential acne treatment it recently acquired. The placing is conditional on sharehold

Evocutis Slides As It Finally Sells Assets To Venn Life Sciences

LONDON (Alliance News) - Evocutis PLC saw its shares slide by a third Wednesday after it finally sold its assets after months of talks, leaving it as an investment shell. In a statement, Evocutis said it had sold all the intellectual property rights for its Labskin product and SYN1113 inves

Venn Life Sciences To Acquire Trade, Business Assets Of CRM Clinical Trials GmbH For EUR0.6M

DIRECTOR DEALINGS: Venn Life Sciences CEO Transfers Shares To Pension Fund

Venn Life Sciences' 1st Half Loss Widens As It Ups Investment Spend

Venn Life Sciences wins new contracts

Venn Life Sciences has won two contracts to provide a number of clinical trial-management services across Europe. The first contract is with a global pharmaceutical company to conduct a Phase IV drug interaction study and the second is with a leading US biotech company to manage a multi-national st

Venn Life Sciences sets up Russian arm

Clinical research company Venn Life Sciences on Thursday said it expanded its operations with a new Russian business. The group has established Venn Russia, a joint venture with a local contract research organisation (CRO). The new arm will operate from offices in Moscow and will complement exist